Current evidence therefore suggests that TREM2 levels in CSF or peripheral blood, although not sensitive enough to serve as a diagnostic biomarker, can predict the risk of early cognitive involvement and dementia in PD patients, and even the risk of motor progression. Here, TREM2 is linked to Parkinson disease.